In the June issue of Managing Intellectual Property
, the publication recognized Finnegan partner Charles E. Lipsey
as one of the top ten U.S. litigators in the life sciences patent industry. Representative matters that Mr. Lipsey worked on include University of California v. Eli Lilly and Co.,
where Finnegan successfully defended Lilly’s human insulin product from infringement allegations, and Eli Lilly & Co. v. Zenith Goldline Pharms
, in which Finnegan successfully obtained for Lilly determination of infringement and validity of a patent on the drug product Zyprexa®.